{
    "nct_id": "NCT04616196",
    "official_title": "A Phase 1b/2, Open-label, Multicenter, Dose Escalation and Dose Expansion Study of NKTR-255 Monotherapy or in Combination With Cetuximab as a Salvage Regimen for Solid Tumors",
    "inclusion_criteria": "* Histologically confirmed diagnosis of a locally advanced or metastatic HNSCC, CRC, cSCC, ASCC, or cervical cancer.\n* Life expectancy > 12 weeks as determined by the Investigator.\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.\n* Measurable disease per RECIST 1.1.\n\nHNSCC:\n\n* Progression on any first or second line platinum-based chemotherapy and/or anti-PD-1 or programmed death-ligand 1 antibody.\n\nCRC:\n\n* Patients must have received or were intolerant to at least 2 prior cancer therapy regimens administered for metastatic disease.\n\ncSCC\n\n* Patients must have received prior therapy including anti-PD-1 and platinum-based chemotherapy, have documented platinum-refractory disease, or be ineligible/unfit for platinum-based therapy.\n\naSCC\n\n* Patients must have received prior therapy including anti-PD-1 and platinum-based chemotherapy, have documented platinum-refractory disease, or be ineligible/unfit for platinum-based therapy.\n* If human immunodeficiency virus (HIV)-positive, patients must also have CD4+ count ≥ 300/μL, undetectable viral load, and be receiving highly active antiretroviral therapy at the time of screening.\n\nCervical Cancer\n\n* Patients must have experienced progression (or toxicity precluding additional treatment) on any first- or second-line platinum-based chemotherapy and anti-PD-(L)1, have documented platinum-refractory disease, or be ineligible/unfit for platinum-based therapy.\n* Patients must have known status by pathology for HPV\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Use of an investigational agent or an investigational device within 28 days before administration of first dose of study drug(s)\n* Prior surgery or radiotherapy within 14 days of initiating study drug(s)\n* Evidence of clinically significant interstitial lung disease or active, noninfectious pneumonitis; active infection requiring systemic therapy within 7 days prior to dosing\n* Patients who have been previously treated with IL-2 or IL-15\n* Known Grade 3 or 4 hypersensitivity reaction to cetuximab, history of allergy to red meat or tick bites, or history of positive test results for immunoglobulin E antibodies against cetuximab\n* Patients who have an active, known, or suspected autoimmune disease\n\nNOTE: Other protocol defined inclusion/exclusion criteria may apply",
    "miscellaneous_criteria": "Key"
}